All In Biotech

Drug Trial Radar · NCT01701973

Effect of DPP4 Inhibition on Growth Hormone Secretion

The Effect of Dipeptidyl Peptidase IV Inhibition on Growth Hormone-Mediated Vasodilation

Last checked: Nov 20, 2026Latest source record: May 29, 2018 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registry

Status

Completed

Enrollment

44

Actual

Start

Jan 2013

Primary completion

May 2017

Study completion May 2017

Sponsor

Lead sponsor
Vanderbilt UniversityAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
National Institutes of Health (NIH); National Heart, Lung, and Blood Institute (NHLBI)
First posted
Oct 5, 2012

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 4
Allocation
Randomized
Model
Crossover
Masking
Double (participant, investigator)
Primary purpose
Other
Who can join
All sexes, from 18 years, up to 40 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

This study tests the following hypotheses: Aim 1: Test the hypothesis that acute dipeptidyl peptidase 4 (DPP4) inhibition with the currently available anti-diabetic drug, sitagliptin, will increase stimulated growth hormone (GH) secretion in healthy lean adults by decreasing the degradation of growth hormone releasing hormone (GHRH). Aim 2: Test the hypothesis that decreased degradation of GHRH during acute DPP4 inhibition will result in an increase in endothelium-dependent vasodilation mediated by GH and independent from GLP1 (glucagon like peptide-1) in healthy lean adults. This study promises to provide novel data regarding how this increasingly used class of anti-diabetic drugs affects the pituitary GH axis and could affect blood vessel relaxation. Growth hormone levels are low in the setting of obesity and pre-diabetes. A further study may evaluate the effect of chronic DPP4 inhibitor therapy in a population of patients with obesity and pre-diabetes.

Conditions

  • Obesity

Interventions

  • SitagliptinDrug

    During Aim 1, given on one of two study days (other study day subjects receive placebo.) During Aim 2, given during both of two study days.

  • PegvisomantDrug

    During Aim 2, given 72 hours prior to one of two study days (Group B subjects only)

  • PlaceboDrug

    During Aim 1, given on one of two study days (other study day subjects receive sitagliptin.) During Aim 2, given on one of two study days (other study day subjects receive either L-NMMA, pegvisomant, or Exendin 9-39 pending their group assignment)

  • L-NMMADrug

    During Aim 2, given during one of two study days (Group A subjects only)

  • Exendin 9-39Drug

    During Aim 2, given during one of two study days (Group C subjects only)

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Aim 1: Stimulated Peak Growth Hormone LevelTime frame: Growth Hormone Level at 30 minutes (i.e. at completion of arginine infusion), 45 minutes, 60 minutes, 90 minutes, 120 minutes, 150 minutes, 180 minutes
  2. Aim 1: Percent Change From Baseline in Forearm Vascular ResistanceTime frame: Percent change from baseline in forearm vascular resistance at 30 minutes, 60 minutes, 90 minutes, 120 minutes, 150 minutes, 180 minutes
  3. Aim 1: Percent Change From Baseline in Forearm Blood FlowTime frame: Percent change from baseline in forearm blood flow at 30 minutes, 60 minutes, 90 minutes, 120 minutes, 150 minutes, 180 minutes.
  4. Aim 2: Percent Change From Baseline in Forearm Blood FlowTime frame: Percent change from baseline in forearm blood flow at 30 minutes, 60 minutes, 90 minutes, 120 minutes, 150 minutes, 180 minutes.
  5. Aim 2: Percent Change From Baseline in Forearm Vascular ResistanceTime frame: Percent change from baseline in forearm vascular resistance at 30 minutes, 60 minutes, 90 minutes, 120 minutes, 150 minutes, 180 minutes

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Vanderbilt University Medical Center

    Nashville, Tennessee

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.